



ÅRSREGNSKAPET FOR REGNSKAPSÅRET 2024 - GENERELL INFORMASJON

Enheten

Organisasjonsnummer: 929 107 209
Organisasjonsform: Aksjeselskap
Foretaksnavn: HORIZON THERAPEUTICS NORWAY AS
Forretningsadresse: Wergelandsveien 7
0167 OSLO

Regnskapsår

Årsregnskapets periode: 01.01.2024 - 31.12.2024

Konsern

Morselskap i konsern: Nei

Regnskapsregler

Regler for små foretak benyttet: Ja
Benyttet ved utarbeidelsen av årsregnskapet til selskapet: Regnskapslovens alminnelige regler

Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: David James Caraher
Dato for fastsettelse av årsregnskapet: 21.01.2025

Grunnlag for avgivelse

År 2024: Årsregnskapet er elektronisk innlevert
År 2023: Tall er hentet fra elektronisk innlevert årsregnskap fra 2024

Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.

Brønnøysundregistrene, 04.02.2025



Resultatregnskap

Beløp i: NOK	Note	2024	2023
RESULTATREGNSKAP			
Lønnskostnad	1		
Driftsresultat			
Netto finans			
Ordinært resultat før skattekostnad		0	0
Skattekostnad på resultat	2		
Ordinært resultat etter skattekostnad		0	0
Årsresultat	3	0	0



Balanse

Beløp i: NOK	Note	2024	2023
BALANSE - EIENDELER			
Anleggsmidler			
Immaterielle eiendeler			
Utsatt skattefordel	2		
Sum anleggsmidler		0	0
Omløpsmidler			
Varer			
Fordringer			
Konsernfordringer		30 000	30 000
Sum fordringer		30 000	30 000
Sum omløpsmidler		30 000	30 000
SUM EIENDELER		30 000	30 000
BALANSE - EGENKAPITAL OG GJELD			
Egenkapital			
Innskutt egenkapital			
Aksjekapital	4	30 000	30 000
Beholdning av egne aksjer	4		
Sum innskutt egenkapital		30 000	30 000
Sum egenkapital	3	30 000	30 000
Gjeld			
Langsiktig gjeld			
Utsatt skatt	2		
Annen langsiktig gjeld			
Sum langsiktig gjeld		0	0



Balanse

Beløp i: NOK	Note	2024	2023
Betalbar skatt	2		
Sum gjeld		0	0
SUM EGENKAPITAL OG GJELD		30 000	30 000
POSTER UTENOM BALANSEN			
Garantistillelser	5		



Brønnøysundregistrene

ÅRSREGNSKAP FOR REGNSKAPSÅRET 2024 - GENERELL INFORMASJON

Journalnummer: 2025 304868

Enheten

Organisasjonsnummer: 929 107 209
Organisasjonsform: Aksjeselskap
Foretaksnavn: HORIZON THERAPEUTICS NORWAY AS
Forretningsadresse: Wergelandsveien 7
0167 OSLO

Regnskapsår

Årsregnskapets periode: 01.01.2024 - 31.12.2024

Konsern

Morselskap i konsern: Nei

Regnskapsregler

Regler for små foretak benyttet: Ja
Benyttet ved utarbeidelsen av
årsregnskapet til selskapet: Regnskapslovens alminnelige regler

Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: David James Caraher
Dato for fastsettelse av årsregnskapet: 21.01.2025

Revisjon

Selskapet har besluttet at årsregnskapet
ikke skal revideres: Ja

Grunnlag for avgivelse

År 2024: Årsregnskap er elektronisk innlevert.
År 2023: Tall er hentet fra elektronisk innlevert årsregnskap fra 2024.

Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.

Brønnøysundregistrene, 03.02.2025



Organisasjonsnr: 929 107 209
HORIZON THERAPEUTICS NORWAY AS

RESULTATREGNSKAP

Beløp i: NOK	Note	2024	2023
RESULTATREGNSKAP			
Lønnskostnad	1		
Driftsresultat			
Netto finans			
Ordinært resultat før skattekostnad		0	0
Skattekostnad på resultat	2		
Ordinært resultat etter skattekostnad		0	0
Årsresultat	3	0	0



Organisasjonsnr: 929 107 209
HORIZON THERAPEUTICS NORWAY AS

BALANSE

Beløp i: NOK	Note	2024	2023
BALANSE - EIENDELER			
Anleggsmidler			
Immaterielle eiendeler			
Utsatt skattefordel	2		
Sum anleggsmidler		0	0
Omløpsmidler			
Varer			
Fordringer			
Konsernfordringer		30 000	30 000
Sum fordringer		30 000	30 000
Sum omløpsmidler		30 000	30 000
SUM EIENDELER		30 000	30 000
BALANSE - EGENKAPITAL OG GJELD			
Egenkapital			
Innskutt egenkapital			
Aksjekapital	4	30 000	30 000
Beholdning av egne aksjer	4		
Sum innskutt egenkapital		30 000	30 000
Sum egenkapital	3	30 000	30 000
Gjeld			
Langsiktig gjeld			
Utsatt skatt	2		
Annen langsiktig gjeld			
Sum langsiktig gjeld		0	0
Betalbar skatt	2		
Sum gjeld		0	0
SUM EGENKAPITAL OG GJELD		30 000	30 000
POSTER UTENOM BALANSEN			
Garantistillelser	5		



Organisasjonsnr: 929 107 209
HORIZON THERAPEUTICS NORWAY AS

NOTEOPPLYSNINGER - SELSKAP - alle poster oppgitt i hele tall

Note

1

Antall årsverk i regnskapsåret
0.00

Sum Beløp

Balanseført verdi 31.12. Varige driftsmidler Immaterielle eiend.

Konsernregnskap

Morselskapet sitt navn

Forretningskontor for morselskapet

Begrunnelse for at datterselskap er utelatt fra konsolideringen

Samlet beløp - tilknyttet selskap Årets Fjorårets

Samlet beløp - foretak i samme konsern Årets Fjorårets

Samlet beløp - foretak i samme konsern Årets Fjorårets

Samlet beløp - felles kontrollert virksomhet Årets Fjorårets

Pantstillelse Beløp

Beholdning av egne aksjer Antall Pålydende Andel av aksjek.



Certificate Of Completion

Envelope Id: 7017C645-8E81-4126-A6D3-58AFB8B8E581 Status: Completed
 Subject: Complete with Docusign: Horizon Therapeutics Norway AS - Financial Statement FY 2024_21.01.202...
 Source Envelope:
 Document Pages: 12 Signatures: 3 Envelope Originator:
 Certificate Pages: 5 Initials: 0 Anke Hagemann
 AutoNav: Enabled 1 Amgen Center Dr
 EnvelopeId Stamping: Enabled Thousand Oaks, CA 91320
 Time Zone: (UTC-08:00) Pacific Time (US & Canada) ankeh@amgen.com
IP Address: 198.176.191.100


Record Tracking

Status: Original Holder: Anke Hagemann Location: DocuSign
 1/21/2025 3:10:47 AM ankeh@amgen.com

Signer Events

Karin Järperud
 knilsson@amgen.com
 Country Sr Director/VD
 Amgen Enterprise DS Viewer Default Account
 Security Level: Email, Account Authentication (None)

Signature

DocuSigned by:

20EE88DF25E342F...
 Signature Adoption: Pre-selected Style
 Using IP Address: 198.176.191.100


Timestamp

Sent: 1/21/2025 3:13:40 AM
 Viewed: 1/22/2025 12:50:53 AM
 Signed: 1/22/2025 12:51:00 AM

Electronic Record and Signature Disclosure:

Accepted: 1/22/2025 12:50:53 AM
 ID: 266a6bea-9a3f-4942-8c3b-781a14ca49c8

Paraskevi Florou
 pflorou@amgen.com
 Finance Director
 Amgen, Inc - CFR Part 11
 Security Level: Email, Account Authentication (None)


DocuSigned by:

01A857D924F04CF...
 Signature Adoption: Pre-selected Style
 Using IP Address: 198.176.191.100

Sent: 1/21/2025 3:13:40 AM
 Viewed: 1/21/2025 2:25:45 PM
 Signed: 1/27/2025 5:13:43 AM

Electronic Record and Signature Disclosure:

Accepted: 1/21/2025 2:25:45 PM
 ID: e4c3ad02-0830-4860-a1be-9c66eb77d51a

Tore von Würden Petersen
 torev@amgen.com
 Country Director
 Amgen Enterprise DS Viewer Default Account
 Security Level: Email, Account Authentication (None)

Signed by:

E9710F4BDE59449...
 Signature Adoption: Drawn on Device
 Using IP Address: 80.208.69.176
 Signed using mobile

Sent: 1/21/2025 3:13:41 AM
 Viewed: 1/24/2025 6:05:20 AM
 Signed: 1/24/2025 6:05:40 AM

Electronic Record and Signature Disclosure:

Accepted: 1/24/2025 6:05:20 AM
 ID: 74813107-6782-4447-9947-758289264fc9

In Person Signer Events

Signature

Timestamp

Editor Delivery Events

Status

Timestamp

Agent Delivery Events

Status

Timestamp

Intermediary Delivery Events

Status

Timestamp

Certified Delivery Events

Status

Timestamp



Carbon Copy Events

Status

Timestamp

Witness Events

Signature

Timestamp

Notary Events

Signature

Timestamp

Envelope Summary Events

Status

Timestamps

Envelope Sent

Hashed/Encrypted

1/21/2025 3:13:41 AM

Certified Delivered

Security Checked

1/24/2025 6:05:20 AM

Signing Complete

Security Checked

1/24/2025 6:05:40 AM

Completed

Security Checked

1/27/2025 5:13:43 AM

Payment Events

Status

Timestamps

Electronic Record and Signature Disclosure



Electronic Record and Signature Disclosure created on: 10/23/2024 8:58:32 AM

Parties agreed to: Karin Järperud, Paraskevi Florou, Tore von Würden Petersen

CONSENT TO USE OF ELECTRONIC SIGNATURE

CONSUMER DISCLOSURE

From time to time, Amgen Inc. (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after signing session and, if you elect to create a DocuSign signer account, you may access them for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Compliance

You agree that any electronic signature used to sign this document shall be treated the same as handwritten signature for the purposes of validity, enforceability and admissibility.

Authorized Representative

Any agreement for signature accessed through a secure link to DocuSign is to be signed by a representative of your organization authorized to bind your organization ("authorized representative"). If you receive an agreement for signature and are not the authorized representative, please reassign the request to the authorized representative by selecting 'Other Actions' in the upper right corner and clicking 'Assign to Someone Else'. You will receive a copy of the fully executed agreement via email upon completion.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind



If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Amgen Inc.

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: docusign@amgen.com

To advise Amgen Inc. of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at docusign@amgen.com and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address. If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Amgen Inc.

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to docusign@amgen.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.



To withdraw your consent with Amgen Inc.

To inform us that you no longer want to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your DocuSign session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to docusign@amgen.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process.

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found: [here](#).

Acknowledging your access and consent to receive materials electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
 - You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic; and
 - Record and Disclosure to a location where you can print it, for future reference and access; and until or unless you notify Amgen Inc. as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Amgen Inc. during the course of your relationship with Amgen Inc.
- br>



DocuSign Envelope ID: 7017C645-8E81-4126-A6D3-58AFB8B8E581



Årsregnskap 2024

Horizon Therapeutics Norway AS

Resultatregnskap
Balanse
Noter til regnskapet



Org.nr.: 929 107 209



DocuSign Envelope ID: 7017C645-8E81-4126-A6D3-58AFB8B8E581

RESULTATREGNSKAP

HORIZON THERAPEUTICS NORWAY AS

DRIFTSINNEKTER OG DRIFTSKOSTNADER	Note	2024	2023
Sum driftsinntekter		0	0
Sum driftskostnader		0	0
FINANSINNEKTER OG FINANSKOSTNADER			
Resultat av finansposter		0	0
Årsresultat	3	0	0

HORIZON THERAPEUTICS NORWAY AS

SIDE 2



DocuSign Envelope ID: 7017C645-8E81-4126-A6D3-58AFB8B8E581

BALANSE			
HORIZON THERAPEUTICS NORWAY AS			
EIENDELER	Note	2024	2023
ANLEGGSMIDLER			
IMMATERIELLE EIENDELER			
Sum immaterielle eiendeler		0	0
VARIGE DRIFTSMIDLER			
FINANSIELLE ANLEGGSMIDLER			
Sum anleggsmidler		0	0
OMLØPSMIDLER			
FORDRINGER			
Konsernfordringer		30 000	30 000
Sum fordringer		30 000	30 000
INVESTERINGER			
Sum omløpsmidler		30 000	30 000
Sum eiendeler		30 000	30 000

HORIZON THERAPEUTICS NORWAY AS

SIDE 3




DocuSign Envelope ID: 7017C645-8E81-4126-A6D3-58AFB8B8E581


BALANSE


HORIZON THERAPEUTICS NORWAY AS

EGENKAPITAL OG GJELD	Note	2024	2023
EGENKAPITAL			
INNSKUTT EGENKAPITAL			
Aksjekapital	4	30 000	30 000
Sum innskutt egenkapital		30 000	30 000
OPPTJENT EGENKAPITAL			
Sum egenkapital	3	30 000	30 000
GJELD			
AVSETNING FOR FORPLIKTELSE			
ANNEN LANGSIKTIG GJELD			
Sum annen langsiktig gjeld		0	0
KORTSIKTIG GJELD			
Sum kortsiktig gjeld		0	0
Sum gjeld		0	0
Sum egenkapital og gjeld		30 000	30 000

Styret i Horizon Therapeutics Norway AS

Signed by:

E9710F4BDE59449...
Tore Von Würden Petersen
styreleder

DocuSigned by:

20EE68DF2FE242E...
Karin Louise Ulrika Järperud
styremedlem

DocuSigned by:

D1A657D924F04CF...
Paraskevi Florou
styremedlem



DocuSign Envelope ID: 7017C645-8E81-4126-A6D3-58AFB8B8E581

Regnskapsprinsipper

Årsregnskapet er satt opp i samsvar med regnskapsloven og NRS 8 - God regnskapsskikk for små foretak.

SKATT

Skattekostnaden i resultatregnskapet omfatter både periodens betalbare skatt og endring i utsatt skatt. Utsatt skatt er beregnet med 22 % på grunnlag av de midlertidige forskjeller som eksisterer mellom regnskapsmessige og skattemessige verdier, samt ligningsmessig underskudd til fremføring ved utgangen av regnskapsåret. Skatteøkende og skattereduserende midlertidige forskjeller som reverserer eller kan reverseres i samme periode er utlignet og nettoført.

Note 1 Lønnskostnader

Horizon Therapeutics Norway AS har ikke hatt lønns- eller personalkostnader i 2024 og det foreligger heller ingen slike forpliktelser.

Note 2 Skatt

Årets skattekostnad	2024	2023
Resultatført skatt på ordinært resultat:		
Betalbar skatt	0	0
Endring i utsatt skattefordel	0	0
Skattekostnad ordinært resultat	0	0
Skattepliktig inntekt:		
Resultat før skatt	0	0
Permanente forskjeller	0	0
Skattepliktig inntekt	0	0
Betalbar skatt i balansen:		
Betalbar skatt på årets resultat	0	0
Sum betalbar skatt i balansen	0	0

Skatteeffekten av midlertidige forskjeller som har gitt opphav til utsatt skatt og utsatte skattefordeler, spesifisert på typer av midlertidige forskjeller

	2024	2023	Endring
Utsatt skatt (22 %)	0	0	0



DocuSign Envelope ID: 7017C645-8E81-4126-A6D3-58AFB8B8E581

Note 3 Egenkapital

	Aksje- kapital	Sum
Pr. 31.12.2023	30 000	30 000
Pr. 01.01.2024	30 000	30 000
Årets overskudd		0
Pr. 31.12.2024	30 000	30 000

Note 4 Aksjonærer

AKSJEKAPITALEN I HORIZON THERAPEUTICS NORWAY AS PR. 31.12 BESTÅR AV:

	Antall	Pålydende	Bokført
Ordinære aksjer	30 000	1,0	30 000
Sum	30 000		30 000

EIERSTRUKTUR

De største aksjonærene i % pr. 31.12 var:

	Ordinære	Eierandel	Stemmeandel
Horizon Therapeutics Irland DAC	30 000	100,0	100,0

Note 5 Hendelser etter balansedagen

Selskapet blir avviklet i januar 2025.